Cargando…
Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer
BACKGROUND: Mediator complex participates in transcriptional regulation by connecting regulatory DNA sequences to the RNA polymerase II initiation complex. Recently, we discovered through exome sequencing that as many as 70% of uterine leiomyomas harbour specific mutations in exon 2 of mediator comp...
Autores principales: | Kämpjärvi, K, Mäkinen, N, Kilpivaara, O, Arola, J, Heinonen, H-R, Böhm, J, Abdel-Wahab, O, Lehtonen, H J, Pelttari, L M, Mehine, M, Schrewe, H, Nevanlinna, H, Levine, R L, Hokland, P, Böhling, T, Mecklin, J-P, Bützow, R, Aaltonen, L A, Vahteristo, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493861/ https://www.ncbi.nlm.nih.gov/pubmed/23132392 http://dx.doi.org/10.1038/bjc.2012.428 |
Ejemplares similares
-
MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas
por: Kämpjärvi, Kati, et al.
Publicado: (2016) -
Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors
por: Mäkinen, Netta, et al.
Publicado: (2017) -
Mutation analysis of components of the Mediator kinase module in MED12 mutation-negative uterine leiomyomas
por: Mäkinen, N, et al.
Publicado: (2014) -
Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12
por: Mäkinen, Netta, et al.
Publicado: (2016) -
Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas
por: Heinonen, Hanna-Riikka, et al.
Publicado: (2017)